(904) 998-0854

JUNE 17-20, 2027 | Nashville, TN

2027 NLA

SCIENTIFIC SESSIONS

REGISTRATION COMING SOON

2026 #NLASessions Agenda

 Thursday, June 11, 2026

3:00 – 3:50 PMExpert Theater | Sponsored by Chiesi Global Rare Disease | Snack provided by the NLASession Title Coming Soon
3:00 – 3:50 PMExpert Theater | Sponsored by Heartflow | Snack provided by the NLARedefining Risk: Leveraging CCTA and Plaque Analysis for Personalized Cardiovascular Prevention
4:00 – 6:00 PMSession I | 2026 Opening Session“Lower for Longer”: Advancing Lipid Management in the Era of Evolving Evidence and 2026 Guideline Updates*Co-hosted with the National Lipid Association and VindicoCME This fast‑paced program begins with an engaging, evidence‑based overview of newly updated guidelines and key clinical trial findings. From there, you’ll dive into real‑world case challenges that explore primary, moderate‑risk, and high‑risk patient scenarios. Through integrated audience polling, you’ll actively test your knowledge and decision‑making on topics such as risk assessment, LDL‑C and Lp(a) management, therapy selection, and treatment escalation.Expert faculty will walk you through each case, break down the most relevant data, and translate emerging evidence into practical, actionable strategies you can apply immediately in your clinical practice.By the end of this session, you’ll feel more confident applying current guidelines, evaluating new and emerging therapies, and supporting team‑based approaches to improving cardiovascular outcomes.*Subject to change based on funding approval.
6:00 – 7:00 PMOpening Night Exhibit Hall Kickoff Reception

 Friday, June 12, 2026 | Decoding Discovery: From Global Mechanism to Patient Medicine

6:45 – 8:45 AM CME Situation Room: Exploring the Cardiovascular and Neurocognitive Implications of CETP Inhibition
Hosted by Vindico Medical Education

This is an independent satellite CME/CE symposium held in conjunction with the NLA 2026 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
8:00 – 9:00 AMBreakfast in Exhibit Hall
9:00 – 10:30 AMSession II | From Genetic Discovery to Clinical ActionCRISPR-Based Gene Editing: Rewriting the Code for Lifetime Lipid Control and Cardiovascular Prevention   Ashish Sarraju, MDGenotype-Informed Prevention: The Economic Case for Cascade Screening in Familial Hypercholesterolemia   William Weintraub, MDUnlocking the Future of Cardiology: The Next Generation of Therapies Driven by Genetic Discovery  David Davidson, MD
10:30 – 11:00 AM Abstract Author Q&A 
10:40 – 10:55 AMFlash Forum | Exhibit Hall | Sponsored by Mirum PharmaceuticalsSession Title Coming Soon
11:00 – 11:20 AMNLA Incoming President’s Address
11:20 AM – 12:00 PM W. Virgil Brown Distinguished Achievement Award LectureshipMy Journey as a Researcher, Clinician, and Patient in the Field of Lipids and Atherosclerosis: Setbacks, Advances, and Opportunities ChristieBallantyne, MD
12:00 – 12:20 PM NLA Scientific Updates 
12:25 – 1:15 PMExpert Theater | Sonsored by Ionis Pharmaceuticals | Lunch provided by the NLATRYNGOLZA: proven results and real-patient experiences
12:25 – 1:15 PMExpert Theater | Sponsored by Kaneka – LIPOSORBER | Lunch provided by the NLASession Title Coming Soon
12:20 – 1:20 PM Lunch in Exhibit Hall
1:20 – 1:50 PMSession III | Late Breakers
1:50 – 2:20 PM Abstract Author Q&A
2:00 – 2:15 PMFlash Forum | Exhibit Hall | Sponsored by AllelicaSession Title Coming Soon
2:20 – 3:50 PMSession IV | Severe Hypertriglyceridemia: A Comprehensive Exploration of Uncommon Causes and Emerging InsightsPersistent Chylomicronemia, Looking Beyond FCS   Zahid Ahmad, MD, FNLA  GPIHBP1 Autoantibody Syndrome Explained   Katsuyuki Nakajima, PhDThe Adipose Deficit: Recognizing Lipodystrophy as a Cause of Severe HTG   Vinaya Simha MBBS, MD
3:50 – 4:20 PM Abstract Author Q&A
4:20 – 6:05 PMSession V | NLA/EAS Joint Session
Primary Prevention of ASCVD: a Joint Session from the European Atherosclerosis Society and the National Lipid AssociationPrimary Prevention & Lp(a): The Updated Guidelines   Bø​rge Nordestgaard, MD, DMScUsing Imaging to Augment Primordial and Primary Prevention   Dinesh Kalra, MD, FNLACombination Drug Therapy to Achieve Guideline Goals   Kausik Ray, MD, FMedSciHow Do We Improve Implementation?   Kaye-Eileen Willard, MD, FNLA

 Saturday, June 13, 2026 | Legacy, Data, and the Next Generation of Care

8:00 – 8:50 AMExpert Theater | Sponsored by Arrowhead Pharmaceuticals, Inc. | Breakfast provided by the NLASession Title Coming Soon
8:00 – 8:50 AMExpert Theater | Sponsored by Regeneron | Breakfast provided by the NLAUncover HoFH, an ultra-rare lipid disorder, and Explore EVKEEZA (evinacumab-dgnb) as a treatment option
8:00 – 9:00 AMBreakfast in Exhibit Hall
9:00 – 10:30 AMSession VI | Rewriting the Rules for Primary Prevention: New Outcomes from Intensive LDL-C Reduction in High-Risk PatientsThe Original PCSK9 Inhibitor Trials: FOURIER, ODYSSEY Outcomes, FOURIER OLE   Bob Giugliano, MDWhat We’ve Learned about LDL-C and Outcomes   Nicholas Marston, MDVESALIUS-CV   Erin Bohula, MD, DPhil
10:30 – 11:00 AM Abstract Author Q&A
10:40 – 10:55 AMFlash Forum | Exhibit Hall | Sponsored by Alexion Pharmaceuticais-AstraZeneca Rare DiseaseLysosomal Acid Lipase Deficiency (LAL-D) Disease Overview
11:00 AM – 12:30 PMSession VII | Abstract Award WinnersNLA Business MeetingHunninghake Familial Hypercholesterolemia (FH) Award:  Early Detection of Familial Hypercholesterolemia Through Point of Care Testing in 2-Year-Olds  Jose Lopez, MS3rd Place Award: Pooled Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, Across Two Phase 3 Trials: CORALreef Lipids and CORALreef HeFH   Christie Ballantyne, MD2nd Place Award: Accelerating Lipoprotein(a) Testing in Community Health Centers Through Quality Improvement and Education  Jeremy Skinner, BS1st Place Award:  GLP-1 Receptor Agonists Rarely Cause Acute Pancreatitis but Induce Noninflammatory Acinar Hypertrophy, Pancreatic Enlargement and Mild Lipase Leak   Jianing Li, MD
12:35 – 1:25 PMExpert Theater | Sponsored by Amgen | Lunch provided by the NLASession Title Coming Soon
12:35 – 1:25 PMExpert Theater | Sponsored by Ionis Pharmaceuticals | Lunch provided by the NLASevere Hypertriglyceridemia (sHTG)An Underrecognized, Life-Threatening Disease
12:30 – 1:30 PM Lunch in Exhibit Hall
1:30 – 2:35 PMSession VIII | Young Investigator Award Winners5th Place Award: Real World Experience with ApoC-III Inhibition in Patients with Persistent Chylomicronemia  Kamil Winnicki, MD4th Place Award: 21-Oxo-Docosanoic Acid, a Fatty Acid ω-Oxidation–Derived Metabolite, Predicts Non-Mild Acute Pancreatitis: Evidence from Longitudinal Metabolomics   Yonghao Chen, MD3rd Place Award: Treatment-Adjusted Phenotyping and Ascertainment Bias Correction Enable Accurate Familial Hypercholesterolemia Diagnosis: The TUDOR Algorithm   Nadar Genedy, MBBS, MRCP2nd Place Award: Opportunistic cardiometabolic risk detection in young blood donors  David Lee, MD1st Place Award: Lipid-Related Polygenic Risk Score and Its Association with Coronary Artery Calcification  Tomoyo Hamana, MD, PhD
2:35 – 2:50 PM Break 
2:50 – 4:00 PMSession IX | Lipid Scholarship Program Case Discussions
4:00 – 4:15 PMBreak
4:15 – 5:45 PMSession X | Managing the Child’s Trajectory: Intervening on Early Cardiometabolic RiskA Generation at Risk: Understanding and Mitigating Insulin Resistance in Youth   Jeanie Tryggestad, MD   Pre-Atherosclerotic Imaging in Pediatrics: Capturing Early Cardiovascular Risk   Justin Zachariah, MDNurturing the Next Generation: A Family Affair of Health   Preneet Cheema Brar, MD, MS
5:45 – 6:05 PMNLA: A Historical Perspective   Ernst Schaefer, MD, FNLA
6:30 – 7:45 PM NLA Honors and Awards Ceremony

 Sunday, June 14, 2026 | Systems in Flux: Redefining Risk and Resilience

8:00 – 9:00 AMBreakfast
9:00 – 10:30 AMSession XI | Deciphering Women’s Risk: New Perspectives on Lipids, Pre-eclampsia, and Navigating HRT in Cardiometabolic HealthWhen Pregnancy Predicts Heart Health: The Critical Role of Lipids in Pre-eclampsia  Tara Nowakthar, DOFrom Caution to Clarity: Re-evaluating the Risk-Benefit Profile of HRT after the FDA Policy Shift  Rachel Novik, DOTeam-Based Care of Women with Cardiovascular Disease: From Pre-Conception Through Pregnancy and Postpartum  Brittany Katz, MD
10:30 – 10:45 AMBreak
10:45 AM – 12:15 PMSession XII | Inflammation: The GI, Metabolic and Renal LinkLipoprotein(a): The Genetic Inflammatory Fuel Driving Total Cardiovascular Risk   Michael Shapiro, DOThe Role of Non-Invasive Imaging in Assessing MASLD-Related Inflammation and Fibrosis  Kathleen Wyne, MD, PhDModulating the Gut Microbiome: A Novel Strategy for Attenuating Inflammation and Reducing Cardiorenal Risk   Michelle Routhenstein, MS, RD, CDCES, CDN
12:15 PMAdjourn